|
1
|
Pohl H and Welch HG: The role of
overdiagnosis and reclassification in the marked increase of
esophageal adenocarcinoma incidence. J Natl Cancer Inst.
97:142–146. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rüdiger Siewert J, Feith M, Werner M and
Stein HJ: Adenocarcinoma of the esophagogastric junction: Results
of surgical therapy based on anatomical/topographic classification
in 1,002 consecutive patients. Ann Surg. 232:353–361. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Botterweck AA, Schouten LJ, Volovics A,
Dorant E and van Den Brandt PA: Trends in incidence of
adenocarcinoma of the oesophagus and gastric cardia in ten European
countries. Int J Epidemiol. 29:645–654. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Edgren G, Adami HO, Weiderpass E and Nyrén
O: A global assessment of the oesophageal adenocarcinoma epidemic.
Gut. 62:1406–1414. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dikken JL, Lemmens VE, Wouters MW,
Wijnhoven BP, Siersema PD, Nieuwenhuijzen GA, van Sandick JW, Cats
A, Verheij M, Coebergh JW and van de Velde CJ: Increased incidence
and survival for oesophageal cancer but not for gastric cardia
cancer in the Netherlands. Eur J Cancer. 48:1624–1632. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brown LM, Devesa SS and Chow WH: Incidence
of adenocarcinoma of the esophagus among white Americans by sex,
stage, and age. J Natl Cancer Inst. 100:1184–1187. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
de Jonge PJ, van Blankenstein M, Grady WM
and Kuipers EJ: Barrett's oesophagus: Epidemiology, cancer risk and
implications for management. Gut. 63:191–202. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Siewert JR, Stein HJ and Feith M:
Adenocarcinoma of the esophago-gastric junction. Scand J Surg.
95:260–269. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Strong VE, D'Amico TA, Kleinberg L and
Ajani J: Impact of the 7th Edition AJCC staging classification on
the NCCN clinical practice guidelines in oncology for gastric and
esophageal cancers. J Natl Compr Canc Netw. 11:60–66. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ma F, Ye H, He HH, Gerrin SJ, Chen S,
Tanenbaum BA, Cai C, Sowalsky AG, He L, Wang H, et al: SOX9 drives
WNT pathway activation in prostate cancer. J Clin Invest.
126:1745–1758. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Marcker Espersen ML, Linnemann D,
Christensen IJ, Alamili M, Troelsen JT and Høgdall E: SOX9
expression predicts relapse of stage II colon cancer patients. Hum
Pathol. 52:38–46. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang X, Ju Y, Zhou MI, Liu X and Zhou C:
Upregulation of SOX9 promotes cell proliferation, migration and
invasion in lung adenocarcinoma. Oncol Lett. 10:990–994. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chakravarty G, Moroz K, Makridakis NM,
Lloyd SA, Galvez SE, Canavello PR, Lacey MR, Agrawal K and Mondal
D: Prognostic significance of cytoplasmic SOX9 in invasive ductal
carcinoma and metastatic breast cancer. Exp Biol Med (Maywood).
236:145–155. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Riemenschnitter C, Teleki I, Tischler V,
Guo W and Varga Z: Stability and prognostic value of Slug, Sox9 and
Sox10 expression in breast cancers treated with neoadjuvant
chemotherapy. Springerplus. 2:6952013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu J, Pan C, Guo L, Wu M, Guo J, Peng S,
Wu Q and Zuo Q: A new mechanism of trastuzumab resistance in
gastric cancer: MACC1 promotes the Warburg effect via activation of
the PI3K/AKT signaling pathway. J Hematol Oncol. 9:762016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zuo Q, Liu J, Zhang J, Wu M, Guo L and
Liao W: Development of trastuzumab-resistant human gastric
carcinoma cell lines and mechanisms of drug resistance. Sci Rep.
5:116342015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jo A, Denduluri S, Zhang B, Wang Z, Yin L,
Yan Z, Kang R, Shi LL, Mok J, Lee MJ and Haydon R: The versatile
functions of Sox9 in development, stem cells, and human diseases.
Genes Dis. 1:149–161. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang H, McKnight NC, Zhang T, Lu ML, Balk
SP and Yuan X: SOX9 is expressed in normal prostate basal cells and
regulates androgen receptor expression in prostate cancer cells.
Cancer Res. 67:528–536. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jiang SS, Fang WT, Hou YH, Huang SF, Yen
BL, Chang JL, Li SM, Liu HP, Liu YL, Huang CT, et al: Upregulation
of SOX9 in lung adenocarcinoma and its involvement in the
regulation of cell growth and tumorigenicity. Clin Cancer Res.
16:4363–4373. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhou CJ, Guo JQ, Zhu KX, Zhang QH, Pan CR,
Xu WH, Wang HJ and Liu B: Elevated expression of SOX9 is related
with the progression of gastric carcinoma. Diagn Cytopathol.
39:105–109. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang H, Leav I, Ibaragi S, Wegner M, Hu
GF, Lu ML, Balk SP and Yuan X: SOX9 is expressed in human fetal
prostate epithelium and enhances prostate cancer invasion. Cancer
Res. 68:1625–1630. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen Q, Song S, Wei S, Liu B, Honjo S,
Scott A, Jin J, Ma L, Zhu H, Skinner HD, et al: ABT-263 induces
apoptosis and synergizes with chemotherapy by targeting stemness
pathways in esophageal cancer. Oncotarget. 6:25883–25896.
2015.PubMed/NCBI
|
|
25
|
Li XL, Chen XQ, Zhang MN, Chen N, Nie L,
Xu M, Gong J, Shen PF, Su ZZ, Weng X, et al: SOX9 was involved in
TKIs resistance in renal cell carcinoma via Raf/MEK/ERK signaling
pathway. Int J Clin Exp Pathol. 8:3871–3881. 2015.PubMed/NCBI
|
|
26
|
Yu JS and Cui W: Proliferation, survival
and metabolism: The role of PI3K/AKT/mTOR signalling in
pluripotency and cell fate determination. Development.
143:3050–3060. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma Y, Qin H and Cui Y: MiR-34a targets
GAS1 to promote cell proliferation and inhibit apoptosis in
papillary thyroid carcinoma via PI3K/Akt/Bad pathway. Biochem
Biophys Res Commun. 441:958–963. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Y, Wang WL, Xie WL, Li LZ, Sun J, Sun
WJ and Gong HY: Puerarin stimulates proliferation and
differentiation and protects against cell death in human
osteoblastic MG-63 cells via ER-dependent MEK/ERK and PI3K/Akt
activation. Phytomedicine. 20:787–796. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Franke TF, Yang SI, Chan TO, Datta K,
Kazlauskas A, Morrison DK, Kaplan DR and Tsichlis PN: The protein
kinase encoded by the Akt proto-oncogene is a target of the
PDGF-activated phosphatidylinositol 3-kinase. Cell. 81:727–736.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mandell JW: Phosphorylation state-specific
antibodies: Applications in investigative and diagnostic pathology.
Am J Pathol. 163:1687–1698. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mandell JW: Immunohistochemical assessment
of protein phosphorylation state: The dream and the reality.
Histochem Cell Biol. 130:465–471. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Slomovitz BM and Coleman RL: The
PI3K/AKT/mTOR pathway as a therapeutic target in endometrial
cancer. Clin Cancer Res. 18:5856–5864. 2012. View Article : Google Scholar : PubMed/NCBI
|
